Cosmetic cross-reference

Curcumin

CAS 458-37-7

Curcumin (CAS 458-37-7) is a Phase 3 pharmaceutical compound with 13 bioactivity targets and 348 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

348

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Curcumin

CAS Number

458-37-7

UNII

IT942ZTH98

InChIKey

VFLDPWHFBUODDF-FCXRPNKRSA-N

ChEMBL ID

CHEMBL140

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL140 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 13 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	22682.470513112887 nM	867	-
-	Potency	26850.228990228014 nM	176	-
-	GI50	10269.248666666666 nM	75	-
-	MIC	685319.9264705882 nM	68	-
-	EC50	13180.076923076924 nM	65	-
-	MIC	448.6004098360656 ug.mL-1	61	-
-	IC50	12.961366666666667 ug.mL-1	30	-
-	Ki	14273.952599999999 nM	30	-
-	Kd	11385.35 nM	19	-
-	GI50	10.459999999999999 ug.mL-1	5	-
-	IC50	259.6666666666667 molar ratio	3	-
-	Kd	0.001351 1/Ms	1	-
-	Ki	5.01 10'5/M	1	-

SOURCE IUPHAR/BPS 2 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
EP300 lysine acetyltransferase EP300	Inhibition	4.599999904632568 pIC50	15383533
TRPV4 TRPV4	Activation	5.179999828338623 pEC50	31664615

SOURCE PharmGKB 2 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

CFTR (PA109) rs77010898

Genotypes AA + AG are associated with response to curcumin and ivacaftor in people with Cystic Fibrosis as compared to genotype GG.

Evidence: -; PMID 27007499

CFTR rs77010898

Cystic Fibrosis

Evidence: 3; PMID 1

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
CURCUMIN	2955	SU	MTHSPL
curcumin	2955	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Curcumin used for in pharmaceutical contexts?

Curcumin (CAS 458-37-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Curcumin?

Curcumin has 348 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal distension, Abdominal pain lower, Abdominal pain upper, Acute kidney injury. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Curcumin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Curcuma Longa Root Extract with EU status "permitted".

What clinical phase is Curcumin in?

Curcumin is rendered with ChEMBL max phase 3.